SMC endorses Alexion’s Ultomiris
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read More
Tag: Zejula
NICE backs GSK’s Zejula in advanced ovarian cancer
Zejula has been recommended for use in newly diagnosed ovarian cancer patients
Read More
New EU approval for GSK’s Zejula
Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status
Read More
GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval
Both PARP inhibitors receive positive opinions from CHMP
Read More
GSK books 19% sales growth for first quarter
Pharmaceutical sales were up 6% on the year ago period
Read More
Zejula successful in advanced ovarian cancer
GlaxoSmithKline presented the results at the ESMO Congress.
Read More
Success for GSK’s Zejula in ovarian cancer
The drug was found to demonstrate significant improvement in progression free survival for women regardless of their biomarker status.
Read More
FDA Priority Review granted for GSK’s Zejula
There are around 7,500 new ovarian cancer cases in the UK every year.
Read More
GSK completes Tesaro deal
GlaxoSmithKline has completed its acquisition of Tesaro, the oncology focused biopharmaceutical company.
Read More
GSK adds to cancer offering with $5.1bn Tesaro buy
GlaxoSmithKline is buying US oncology biopharma Tesaro for $5.1 billion, marking the first major purchase by the firm since chief executive Emma Walmsley took charge last year.
Read More
NICE asks Tesaro to submit CDF application for Zejula
Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
Read More
EU approves post-chemo option for patients with ovarian cancer
European regulators have cleared Tesaro’s Zejula, offering a new option for the maintenance treatment of certain adults with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
